# FDA Grants Priority Review to AstraZeneca’s Gastric Cancer Application

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/61388
Published: 2026-11-19T13:53:12.000Z
Updated: 2026-11-19T13:53:12.000Z
Section: Regulation

> The biologics license application seeks U.S. approval of sonesitatug vedotin, also known as Sone-Ve.

AstraZeneca’s application for its gastric cancer therapy sonesitatug vedotin received priority review from the U.S. Food and Drug Administration on Nov. 19, advancing the company’s request for U.S. approval.

The agency accepted the biologics license application for sonesitatug vedotin, also known as Sone-Ve, and issued priority review for the filing. The application seeks approval to use the therapy against gastric cancer.


